OraSure Technologies, Inc. ( OSUR ) NASDAQ Global Select

Cena: 3.14 ( 2.78% )

Aktualizacja 07-03 17:04
NASDAQ Global Select
Branża: Medical - Instruments & Supplies
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 638
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 96%
Ilość akcji: 73 484 300
Debiut giełdowy: 1986-11-17
WWW: https://www.orasure.com
CEO: Ms. Carrie Eglinton Manner
Adres: 220 East First Street
Siedziba: 18015 Bethlehem
ISIN: US68554V1089
Opis firmy:

Orasure Technologies, Inc., wraz z spółkami zależnymi, opracowuje, produkuje, rynki i sprzedaje doustne produkty diagnostyczne i urządzenia do gromadzenia próbek w Stanach Zjednoczonych, Europie i na arenie międzynarodowej. Działa w dwóch segmentach, diagnostyce i roztworach molekularnych. Główne produkty firmy obejmują InteliswaB COVID-19 Rapid Test, Inteliswab COVID-19 Rapid Test Pro, Inteliswab COVID-19 Rapid Rx, test szybkiego HIV, Test Oraquick-Home HOV, urządzenie z kolekcji HIV Oraquick Self Fluid Insioniction in Fluid insed in in Melanion in-in-insionict insed in insed in in Melonection in insed in insed in in Melonection in-in in insed we inni insing in in insed in in insed in in insed in in insed we inni inni insed in insed in insed in in insed in in in insed in in in. z badaniami przesiewowymi i potwierdzającymi przeciwciała HIV-1; Przechwytywanie systemów testowania leków; Testy i odczynniki immunologiczne; i Q.E.D. Test alkoholu w ślinie. Oferuje również produkty genomowe pod markami oragene i oracollect; produkty do zbierania mikrobiomów; oraz genofind genomiki usługi laboratoryjne. Ponadto firma zapewnia urządzenia Oracollect, RNA i Omnigene i RAL do użytku w związku z testowaniem molekularnym Covid-19; Oferuje urządzenie do kolekcji Colli-Pee do objętościowej kolekcji pierwszej pustki moczu; oraz produkuje i sprzedaje zestawy używane do zbierania, stabilizacji, transportu i przechowywania próbek materiału genetycznego do testów molekularnych w badaniach akademickich i zastosowaniach komercyjnych, w tym pochodzenia, zarządzania ryzykiem choroby, stylu życia i testowania zwierząt. Ponadto zapewnia inne produkty diagnostyczne, takie jak testy immunologiczne i inne testy diagnostyczne in vitro. Firma sprzedaje swoje produkty w laboratoriach klinicznych, szpitalach, klinikach, organizacjach społecznych i innych organizacjach zdrowia publicznego, dystrybutorów, agencjach rządowych, biur lekarzy oraz podmiotach komercyjnych i przemysłowych. Orasure Technologies, Inc. został włączony w 2000 roku i ma siedzibę w Betlejem w Pensylwanii.

Wskaźniki finansowe
Kapitalizacja (USD) 235 246 315
Aktywa: 464 085 000
Cena: 3.14
Wskaźnik Altman Z-Score: 5.5
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -7.5
Ilość akcji w obrocie: 96%
Średni wolumen: 701 231
Ilość akcji 74 800 100
Wskaźniki finansowe
Przychody TTM 184 612 000
Zobowiązania: 38 520 000
Przedział 52 tyg.: 2.36 - 4.92
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: -0.4
P/E branży: 29.9
Beta: 0.046
Raport okresowy: 2025-08-04
WWW: https://www.orasure.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Kathleen Gallagher Weber Chief Product Officer 920 426 1967
Mr. Kenneth J. McGrath Chief Financial Officer 856 495 1973
Ms. Carrie Eglinton Manner President, Chief Executive Officer & Director 1 828 130 1975
Mr. Stefano Taucer General Counsel & Corporate Secretary 0 0
Amy Steigerwalt Senior Vice President of Human Resources 0 0
Ms. Michele Anthony Senior Vice President, Chief Accounting Officer, Controller & Assistant Secretary 0 1975
Mr. Jason Michael Plagman Vice President of Investor Relations 0 0
Mr. David A. Rappaport C.F.A. Senior Vice President Corporate Development, Strategy & Integration 0 0
Mr. Rafal Iwasiow Ph.D. Vice President of Science, Innovation & Technology 0 0
Mr. Zachary Wert Senior Vice President of Global Operations 0 0
Wiadomości dla OraSure Technologies, Inc.
Tytuł Treść Źródło Aktualizacja Link
OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. 2025 First Quarter Earnings Conference Call. seekingalpha.com 2025-05-08 00:01:48 Czytaj oryginał (ang.)
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates OraSure Technologies (OSUR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago. zacks.com 2025-05-07 23:01:03 Czytaj oryginał (ang.)
OraSure Technologies: Historically Cheap OraSure Technologies shares have dipped below $3 since my last writing, making shares even cheaper. Recent developments at the company include the acquisition of Sherlock Biosciences and the announcement of a $40 million share repurchase program. OSUR is enhancing business efficiency through cost cuts and aims to expand gross margins to 50% by year-end 2025, mitigating acquisition-related cash burn. seekingalpha.com 2025-04-30 19:47:53 Czytaj oryginał (ang.)
OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. globenewswire.com 2025-04-23 20:05:00 Czytaj oryginał (ang.)
OraSure Announces $40 Million Stock Repurchase Program BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand. globenewswire.com 2025-03-24 09:30:00 Czytaj oryginał (ang.)
OraSure Technologies, Inc. (OSUR) Q4 2024 Earnings Call Transcript OraSure Technologies, Inc. (NASDAQ:OSUR ) Q4 2024 Results Conference Call February 25, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Casey Woodring - JPMorgan Andrew Cooper - Raymond James Operator Welcome to the OraSure Technologies, Inc. 2024 Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-02-27 07:49:07 Czytaj oryginał (ang.)
OraSure Technologies (OSUR) Reports Q4 Loss, Tops Revenue Estimates OraSure Technologies (OSUR) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.22 per share a year ago. zacks.com 2025-02-25 21:10:21 Czytaj oryginał (ang.)
OraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th BETHLEHEM, Pa., Feb. 14, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2024 financial results and certain business developments for 5 p.m. ET on February 25, 2025. globenewswire.com 2025-02-14 10:45:00 Czytaj oryginał (ang.)
OraSure (OSUR) Upgraded to Strong Buy: What Does It Mean for the Stock? OraSure (OSUR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2025-01-27 15:00:35 Czytaj oryginał (ang.)
New Strong Buy Stocks for January 27th ALNY, HBT, APH, GNTY and OSUR have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2024. zacks.com 2025-01-27 09:06:13 Czytaj oryginał (ang.)
Should Value Investors Buy OraSure Technologies (OSUR) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-01-23 12:46:28 Czytaj oryginał (ang.)
New Strong Buy Stocks for January 16th MRCY, BBCP, OSUR, VIK and IFS have been added to the Zacks Rank #1 (Strong Buy) List on January 16, 2025. zacks.com 2025-01-16 09:16:10 Czytaj oryginał (ang.)
OraSure to Present at the J.P Morgan Healthcare Conference BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure's presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT. globenewswire.com 2025-01-07 18:05:00 Czytaj oryginał (ang.)
Are Investors Undervaluing OraSure Technologies (OSUR) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-01-07 13:06:56 Czytaj oryginał (ang.)
CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence of the release (read "OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents.") is incomplete. The corrected release follows: globenewswire.com 2025-01-07 10:50:00 Czytaj oryginał (ang.)
OraQuick® HIV Self-Test Now Approved for Use in Adolescents BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older. globenewswire.com 2025-01-07 09:05:00 Czytaj oryginał (ang.)
OSUR Stock Rises Following the Acquisition of Sherlock Biosciences OraSure announces acquisition of Sherlock Biosciences to strengthen its molecular diagnostics portfolio. zacks.com 2024-12-26 14:11:24 Czytaj oryginał (ang.)
OraSure Technologies Acquires Sherlock Biosciences BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. globenewswire.com 2024-12-19 18:02:00 Czytaj oryginał (ang.)
OraSure Technologies: Discounted Assets With An Attractive Free Call Option OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appreciation. seekingalpha.com 2024-12-11 15:34:44 Czytaj oryginał (ang.)
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). globenewswire.com 2024-12-02 09:05:00 Czytaj oryginał (ang.)
Is OraSure Technologies (OSUR) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-11-28 12:41:17 Czytaj oryginał (ang.)
OraSure to Participate in Upcoming Investor Conference BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: globenewswire.com 2024-11-18 18:05:00 Czytaj oryginał (ang.)
Is OraSure Technologies (OSUR) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-11-12 12:45:39 Czytaj oryginał (ang.)
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript seekingalpha.com 2024-11-07 01:05:27 Czytaj oryginał (ang.)
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates OraSure Technologies (OSUR) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.27 per share a year ago. zacks.com 2024-11-06 21:00:54 Czytaj oryginał (ang.)
OraSure Reports Q3 '24 Revenue of $39.9 Million Q3 GAAP EPS of $(0.06) ; Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2024. globenewswire.com 2024-11-06 18:05:00 Czytaj oryginał (ang.)
OraSure: An NCAV Diamond In The COVID Rough OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value (NCAV). At the same time, OraSure has a stable operational history with consistent normalized cash flow margins. seekingalpha.com 2024-11-04 11:32:47 Czytaj oryginał (ang.)
OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. globenewswire.com 2024-10-22 20:05:00 Czytaj oryginał (ang.)
Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc On September 30, 2024, Neuberger Berman Group LLC, a prominent investment firm, made a significant addition to its investment portfolio by acquiring 3,927,692 shares of OraSure Technologies Inc (OSUR, Financial). This transaction, executed at a price of $4.27 per share, marks a notable increase in the firm's holdings in the medical devices sector. gurufocus.com 2024-10-04 20:03:41 Czytaj oryginał (ang.)
OraSure Technologies Elects Jack Kenny to the Board of Directors BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure's Board of Directors currently has seven members. globenewswire.com 2024-09-09 11:05:00 Czytaj oryginał (ang.)
OraSure Technologies Inc (OSUR) Q2 2024 Earnings Call Transcript OraSure Technologies Inc (NASDAQ:OSUR ) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - President and Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Andrew Cooper - Raymond Jones Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies Incorporated 2024 Second Quarter Earnings Conference Call. seekingalpha.com 2024-08-07 01:04:07 Czytaj oryginał (ang.)
OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates OraSure Technologies (OSUR) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.07 per share a year ago. zacks.com 2024-08-06 23:27:06 Czytaj oryginał (ang.)
OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th BETHLEHEM, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2024 financial results and certain business developments for 5 p.m. ET on August 6, 2024. globenewswire.com 2024-07-22 20:05:00 Czytaj oryginał (ang.)
OraSure Technologies Supports National HIV Testing Day BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced its support of HIV testing initiatives taking place across the nation in recognition of National HIV Testing Day, held each year on June 27th. These testing initiatives will help encourage thousands of people across the U.S. to get tested for HIV. globenewswire.com 2024-06-27 11:05:00 Czytaj oryginał (ang.)
OraSure Technologies (OSUR) Q1 Earnings Meet Estimates OraSure Technologies (OSUR) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.37 per share a year ago. zacks.com 2024-05-08 23:20:33 Czytaj oryginał (ang.)
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024. globenewswire.com 2024-04-22 12:00:00 Czytaj oryginał (ang.)